$BVAXF Poised for Breakout Growth in 2026 Revolutionizing Immunotherapy with DPX™ Platform
~ Undervalued Asset Acquisition — BioVaxys acquired IMV Inc.'s entire IP portfolio, including the DPX™ platform and over 120 patents, for $1M in 2024—assets backed by ~$300M in prior investment, positioning the company as significantly undervalued at current ~$8-10M CAD market cap.
~ DPX™ Platform Edge — Proprietary lipid-in-oil formulation delivers controlled release, versatile cargo (peptides, mRNA, etc.), and strong antigen presentation for persistent T-cell responses; superior to emulsions/LNPs with excellent safety and broad applications in oncology, infectious diseases, and allergies.
~ Proven Leadership — Team led by CEO James Passin (successful biotech exits), COO Kenneth Kovan (30+ years pharma), and CMO Dr. David Berd (cancer vaccine pioneer); focused on out-licensing and low-cost R&D to unlock value.
~ Clinical Momentum — Positive Phase 1 data for MVP-S in HR+/HER2- breast cancer (Dec 2025); pipeline includes DPX-RSV (Phase 1 complete), oncology assets targeting out-licensing (e.g., ovarian), and collaborations like Sona Nanotech for novel therapies.
~ Revenue Potential — Royalty-bearing licenses with Zoetis and SpayVac advancing to commercialization (wildlife/aquaculture); near-term royalties expected in 2026, plus mRNA/partnership opportunities in massive markets.
~ 2026 Outlook — Strengthened expertise (e.g., Dr. Tartaglia, Dr. Stanford); reduced financial milestones minimize risk; aggressive BD for licensing/collaborations poised to drive catalysts and shareholder value.
~ Undervalued Asset Acquisition — BioVaxys acquired IMV Inc.'s entire IP portfolio, including the DPX™ platform and over 120 patents, for $1M in 2024—assets backed by ~$300M in prior investment, positioning the company as significantly undervalued at current ~$8-10M CAD market cap.
~ DPX™ Platform Edge — Proprietary lipid-in-oil formulation delivers controlled release, versatile cargo (peptides, mRNA, etc.), and strong antigen presentation for persistent T-cell responses; superior to emulsions/LNPs with excellent safety and broad applications in oncology, infectious diseases, and allergies.
~ Proven Leadership — Team led by CEO James Passin (successful biotech exits), COO Kenneth Kovan (30+ years pharma), and CMO Dr. David Berd (cancer vaccine pioneer); focused on out-licensing and low-cost R&D to unlock value.
~ Clinical Momentum — Positive Phase 1 data for MVP-S in HR+/HER2- breast cancer (Dec 2025); pipeline includes DPX-RSV (Phase 1 complete), oncology assets targeting out-licensing (e.g., ovarian), and collaborations like Sona Nanotech for novel therapies.
~ Revenue Potential — Royalty-bearing licenses with Zoetis and SpayVac advancing to commercialization (wildlife/aquaculture); near-term royalties expected in 2026, plus mRNA/partnership opportunities in massive markets.
~ 2026 Outlook — Strengthened expertise (e.g., Dr. Tartaglia, Dr. Stanford); reduced financial milestones minimize risk; aggressive BD for licensing/collaborations poised to drive catalysts and shareholder value.
